Clinical trial
The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: an Adaptive Phase II/III Randomized Trial.
NCT02685397 is registered in ClinicalTrials.gov with Sir Mortimer B. Davis - Jewish General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: an Adaptive Phase II/III Randomized Trial.
- Lead sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Phase
- Phase 2/3
- Overall status
- Active, not recruiting
- Start date
- October 31, 2016
- Completion date
- August 31, 2041
- Enrollment
- 102 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
castration-resistant prostate cancer patients with oligometastases